Neuroleptic-like and antipsychotic effects of gamma-type endorphins.
D000818:Animals; D014150:Antipsychotic Agents / Q000627:therapeutic use*; D001522:Behavior, Animal / Q000187:drug effects; D004298:Dopamine / Q000378:metabolism; D004311:Double-Blind Method; D004723:Endorphins / Q000627:therapeutic use*; D006801:Humans; D010446:Peptide Fragments / Q000627:therapeutic use; D011569:Psychiatric Status Rating Scales; D011618:Psychotic Disorders / Q000188:drug therapy*; D051381:Rats; D011954:Receptors, Dopamine / Q000187:drug effects; D011957:Receptors, Opioid / Q000187:drug effects; D012559:Schizophrenia / Q000188:drug therapy; D012565:Schizophrenic Psychology; D001615:beta-Endorphin; D018823:gamma-Endorphin
D014150:Antipsychotic Agents; D004723:Endorphins; D010446:Peptide Fragments; D011954:Receptors, Dopamine; D011957:Receptors, Opioid; D001615:beta-Endorphin; D018823:gamma-Endorphin; C018903:gamma-endorphin, des-Tyr(1)-; C033558:des-enkephalin-gamma-endorphin; D004298:Dopamine